期刊
BRITISH JOURNAL OF CANCER
卷 99, 期 12, 页码 2006-2012出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6604808
关键词
ASA404; AS1404; DMXAA; VDA; tumour-VDA; non-small cell lung cancer
类别
资金
- Antisoma Research Limited, London, UK
ASA404 (5,6-dimethylxanthenone-4-acetic acid or DMXAA) is a small-molecule tumour-vascular disrupting agent (Tumour-VDA). This randomised phase II study evaluated ASA404 plus standard therapy of carboplatin and paclitaxel in patients with histologically confirmed stage IIIb or IV non-small cell lung cancer (NSCLC) not previously treated with chemotherapy. Patients were randomised to receive <= 6 cycles of carboplatin area under the plasma concentration-time curve 6mg ml(-1) min and paclitaxel 175 mg m(-2) (CP, n = 36) or standard therapy plus ASA404 1200 mg m(-2) (ASA404-CP, n 37). There was little change in the systemic exposure of either total or free carboplatin or paclitaxel on addition of ASA404. Safety profiles were similar and manageable in both groups, with most adverse effects attributed to standard therapy. Tumour response rate (31 vs 22%), median time to tumour progression (5.4 vs 4.4 months) and median survival (14.0 vs 8.8 months, hazard ratio 0.73, 95% CI 0.39, 1.38) were improved in the ASA404 combination group compared with the standard therapy group. In conclusion, this study establishes the feasibility of combining ASA404 with carboplatin and paclitaxel in patients with previously untreated, advanced NSCLC, demonstrating a manageable safety profile and lack of adverse pharmacokinetic interactions. The results indicate that there may be a benefit associated with ASA404, but this needs to be evaluated in a larger trial.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据